September 10, 2018
WELLESLEY, Mass., Sep. 10, 2018 – Due to the ability to accurately screen pregnant women for multiple chromosomal conditions without the threat of miscarriage, the global market for non-evasive prenatal testing has reached new heights according to a new report from BCC Research.
In 2018, the global market for non-evasive prenatal testing was worth $1.9 billion. BCC Research estimates that it will reach a value of $3.1 billion by 2023, indicating a compound annual growth rate (CAGR) of 10.2%, according to Next Generation Sequencing for Non-Evasive Prenatal Testing: Global Insights.
Major companies that are influencing the industry include Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories and Quest Diagnostics, Inc.
“North America held the largest share of the global NIPT market in terms of revenue,” the report notes. “This can be attributed to the presence of major players in the U.S. and relatively high awareness levels about NIPT in North America. Europe is the second largest market for NIPT. In Europe, market growth largely depends upon increasing penetration of U.S. based tests and their increasing acceptance.”
Editors/reporters requesting analyst interviews should contact Eric Surber at email@example.com.
Next Generation Sequencing for Non-invasive Prenatal Testing: Global Insights( BIO173A )
Publish Date: Aug 2018
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.